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Abstract: CRE (KPC, NDM-1 and OXA-48 type carbapenemase
producers) infections, increasingly encountered across the globe,
are associated with substantial (up to 40%) mortality. Treatment
options are limited due to in-vitro resistance to virtually all classes
of antimicrobials. In-vitro, polymyxins (colistin and polymyxin
B) and tigecycline remain active against majority of CRE iso-
lates. Treatment recommendations are difﬁcult to formulate due
to absence of evidence from randomized clinical trials, and paucity
of published studies on treatment outcomes in infections caused
by NDM-1 producers; most of the studies have been on patients
with KPC-producing K pneumoniae infections. Based on the review
of available evidence (in-vitro and observational studies), the fol-
lowing strategies can be recommended for appropriate therapy
of CRE infections: Optimal dosing of colistin and carbapenems: A
loading dose followed by high-dose extended-interval colistin reg-
imen has been reported to have good efﬁcacy (clinical cure 82%)
in treatment of CRE infections. For CRE strains with low MICs (up
to 4g/ml), prolonged infusion of high-dose carbapenem has been
shown to improve free time above MIC required for bactericidal
effect of carbapenems. Carbapenem monotherapy may be consid-
ered in rare cases of infections caused by CRE strainswith low-level
carbapenemresistance,withadequate source control. Combination
therapy: A recent systematic review has shown that combina-
tion therapy (≥2 antimicrobials active in-vitro – colistin with a
carbapenem, tigecycline or gentamicin) results in better survival
when compared to monotherapy. The mortality was lowest among
patients who received carbapenem-containing combinations, and
those with lower meropenem MICs.
Tigecycline monotherapy is not considered a good option for
treatment of serious CRE infections, as the serum concentrations
achieved are well below the MIC of these organisms. CRE isolate
remain susceptible to fosfomycin, which could be used for treat-
ment of CRE urinary tract infections.
In summary, optimal dosing and combination of at least two
antimicrobials, preferably colistin with a carbapenem seems to be
the most appropriate therapy for severe CRE infections.
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